Clinic of Haematology, University Clinical Centre of Serbia, Belgrade, Serbia.
Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Hamostaseologie. 2021 Oct;41(5):397-399. doi: 10.1055/a-1554-6432. Epub 2021 Sep 20.
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired clonal haematological disease characterized by complement-mediated haemolysis, bone marrow failure and venous thrombosis. Anticomplement therapy eculizumab improves survival and reduces complications. Severe acute respiratory distress syndrome corona virus 2 (SARS-CoV-2) disease 2019 (COVID-19) is associated with high incidence of both venous and arterial thrombosis in hospitalized patients with pneumonia. Deep venous thrombosis (DVT) as the presenting symptom of COVID-19 is a rare event. We describe a well-controlled PNH patient on eculizumab for more than 5 years who presented with DVT, while on warfarin, as the first sign of COVID-19. To our knowledge, this is the first described case of DVT in a PNH patient with COVID-19.
阵发性睡眠性血红蛋白尿症（PNH）是一种罕见的后天性克隆性血液病，其特征为补体介导的溶血、骨髓衰竭和静脉血栓形成。抗补体治疗依库珠单抗可改善生存并减少并发症。严重急性呼吸窘迫综合征冠状病毒 2（SARS-CoV-2）病 2019（COVID-19）与住院肺炎患者静脉和动脉血栓形成的高发病率相关。以深静脉血栓形成（DVT）为首发症状的 COVID-19 较为罕见。我们描述了一名 PNH 患者，该患者在接受依库珠单抗治疗超过 5 年后，在 COVID-19 期间出现 DVT，当时正在服用华法林。据我们所知，这是首例 COVID-19 合并 PNH 患者发生 DVT 的病例。
